AUTL
Autolus Therapeutics plc
There isn't enough reported data to score AUTL yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
AUTL Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Under pressure | |
| Unavailable |
AUTL's profitability and cash flow are currently under pressure. There isn't enough data to rate its revenue and balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
AUTL PE Valuation
AUTL has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
AUTL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect AUTL's losses to shrink, with revenue growing.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
AUTL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.97 | -$0.14 |
| Q2 2026 | -$1.06 | -$0.22 |
| Q1 2026 | -$1.09 | -$0.21 |
| Q4 2025 | -$1.08 | -$0.22 |
| Q3 2025 | -$0.83 | +$0.39 |
| Q2 2025 | -$0.84 | +$0.33 |
| Q1 2025 | -$0.88 | +$0.33 |
| Q4 2024 | -$0.86 | +$0.34 |
AUTL is still losing money, but far less than before: $0.97 per share over the past year, against $2.77 at its worst in late 2019.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over AUTL on earnings quality, reporting a profit while its opponent remains loss making.
AUTL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $41.2M | +95% |
| Q2 2026 | $45.7M | +118% |
| Q1 2026 | $26.2M | +192% |
| Q4 2022 | $3.8M | +2025% |
| Q3 2022 | $2.4M | +904% |
| Q4 2021 | $180K | -55% |
| Q3 2021 | $236K | -65% |
| Q2 2021 | $1.6M | +461% |
AUTL's revenue has grown year over year for seven quarters in a row: $41M last quarter, up 95% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -106% | +232 points |
| Q2 2026 | -96% | +197 points |
| Q1 2026 | -227% | +499 points |
| Q4 2025 | -298% | N/A |
| Q3 2025 | -338% | N/A |
| Q2 2025 | -293% | N/A |
| Q1 2025 | -726% | N/A |
| Q1 2023 | -2738% | N/A |
AUTL's operating margin was −106% last quarter, up 232 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over AUTL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over AUTL on profitability, with a higher operating margin.
AUTL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$19.8M | +$52.5M |
| Q2 2026 | -$26M | +$54.1M |
| Q1 2026 | -$68M | +$15.8M |
| Q4 2025 | -$66.4M | -$17.4M |
| Q3 2025 | -$72.3M | +$14M |
| Q2 2025 | -$80.1M | -$28.1M |
| Q1 2025 | -$83.8M | -$42.8M |
| Q4 2024 | -$49M | -$22.7M |
AUTL has burned cash in almost every quarter: −$180M over the past year, against −$285M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over AUTL on cash generation, producing positive trailing cash flow while its opponent burns cash.
AUTL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +44.8K shares |
| 1 year | 0% | +62.2K shares |
| 3 years | +53% | +92.3M shares |
| 5 years | +276% | +195M shares |
| Available history | +434% | +216M shares |
AUTL has 266M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over AUTL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
AUTL Net Leverage
AUTL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
AUTL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.0 | Neutral |
| Stochastic | 6.1 | Oversold |
AUTL's weekly RSI is 35 (neutral) and its Stochastic is 6 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
AUTL PE vs Healthcare Sector
AUTL has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AUTL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.57 | 24% below |
| 20 week MA | $1.76 | 32% below |
| 50 week MA | $1.63 | 27% below |
| 100 week MA | $1.73 | 31% below |
| 200 week MA | $2.71 | 56% below |
AUTL is in a downtrend: it's below all five of its weekly moving averages, and 56% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over AUTL on trend strength, trading above more of its moving averages.
AUTL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.6 | $8.90 | -35% |
| 2021 | $8.90 | $5.46 | -39% |
| 2022 | $5.46 | $1.86 | -66% |
| 2023 | $1.86 | $6.44 | +246% |
| 2024 | $6.44 | $2.26 | -65% |
| 2025 | $2.26 | $1.67 | -26% |
| 2026 YTD | $1.67 | $1.19 | -29% |
AUTL's yearly returns have swung widely, from +246% in 2023 to −66% in 2022. It's down 29% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over AUTL on returns for 2026, with the stronger performance.